<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02271230</url>
  </required_header>
  <id_info>
    <org_study_id>2014P001206</org_study_id>
    <nct_id>NCT02271230</nct_id>
  </id_info>
  <brief_title>Intervention With Vitamin D and Omega-3 Supplements and Incident Heart Failure</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <brief_summary>
    <textblock>
      This study will examine whether an intervention with vitamin D or fish oil supplements can
      reduce the risk of heart failure among adult men and women during a follow up period of up to
      five years (starting from the time of randomization into the parent VITAL trial). The
      investigators hypotheses are that both vitamin D and fish oil supplements will each reduce
      the risk of heart failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For this ancillary study of the ongoing parent VITAL trial, we will adjudicate incident heart
      failure cases occurring during a time period of up to five years starting from randomization
      of subjects in the parent VITAL study. Intention-to-treat analysis will be used to assess the
      efficacy of vitamin D as well as omega-3 fatty acids.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incident heart failure hospitalization</measure>
    <time_frame>up to five years (starting from the time of randomization into the parent VITAL trial)</time_frame>
    <description>We will consider any hospitalization for heart failure among participants enrolled in the parent VITAL trial for this ancillary study.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">25875</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2000 IU per day and 1 g per day of fish oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vitamin D alone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2000 IU Vitamin D and fish oil placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil (EPA/DHA) alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1 g per day of fish oil and vitamin D placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fish oil and vitamin D placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for both vitamin D and fish oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D and fish oil</intervention_name>
    <description>2000 IU vitamin D and 1g/d fish oil</description>
    <arm_group_label>Vitamin D and fish oil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Fish oil (EPA/DHA) alone</intervention_name>
    <description>1 g/d fish oil</description>
    <arm_group_label>Fish oil (EPA/DHA) alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin D alone</intervention_name>
    <description>2000 IU vitamin D</description>
    <arm_group_label>Vitamin D alone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Vitamin D placebo and fish oil placebo</description>
    <arm_group_label>Fish oil and vitamin D placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men aged 50 or older or women aged 55 or older

          -  Be consuming no more than 800 IU of vitamin D from all supplemental sources combined
             (individual vitamin D supplements, calcium+vitamin D supplements, medications with
             vitamin D [e.g., Fosamax Plus D], and multivitamins), or, if taking, willing to
             decrease or forego such use during the trial;

          -  Be consuming no more than 1200 mg/d of calcium from all supplemental sources combined,
             or, if taking, willing to decrease or forego such use during the trial;

          -  Not be taking fish oil supplements, or, if taking, willing to forego their use during
             the trial

        Exclusion Criteria:

          -  prevalent heart failure

          -  History of cancer (except non-melanoma skin cancer), heart attack, stroke, transient
             ischemic attack, angina pectoris, CABG, or PCI

          -  History of renal failure or dialysis, hypercalcemia, hypo- or hyperparathyroidism,
             severe liver disease (cirrhosis), or sarcoidosis or other granulomatous diseases such
             as active chronic tuberculosis or Wegener's granulomatosis;

          -  Allergy to fish or soy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vitalstudy.org/</url>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 7, 2014</study_first_submitted>
  <study_first_submitted_qc>October 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 22, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Luc Djousse</investigator_full_name>
    <investigator_title>Director of Research, Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

